Search

Displaying results 181 - 190 of 3917 in total
  1. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    [L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). … On October 2021, Incyte Biosciences withdrew its application for a marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal.

  2. Drug

    Strontium ranelate

    go.drugbank.com/drugs/DB09267
    ApprovedWithdrawn

    This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and, simultaneously, reduces the resorption of bone by osteoclasts. … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone Diseases
  3. Drug

    Tolbutamide

    go.drugbank.com/drugs/DB01124
    Approved

    Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.

  4. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC).

  5. Drug

    Choline C 11

    go.drugbank.com/drugs/DB09277
    Approved

    Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes. It was developed by MCPRF and FDA first approved in Septe...

  6. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    FDA approved March 27, 2012.

  7. Drug

    Coagulation factor VII human

    go.drugbank.com/drugs/DB13150
    ApprovedInvestigational

    Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

  8. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing … the data [A235720] and aducanumab was granted accelerated FDA approval on 7 June 2021.

  9. Drug

    Isoflavone

    go.drugbank.com/drugs/DB12007
    ApprovedInvestigationalWithdrawn

    Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.

  10. Drug

    Dipotassium phosphate

    go.drugbank.com/drugs/DB09414
    ApprovedInvestigational

    Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.

    Mixtures: TRAVASOL SOLUCION 8.5% CON ELECTROLITOS, ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI